DZ BANK, together with MUFG Bank, served as sell-side financial advisors to the shareholders of Lomapharm on the sale to Bionorica

DZ BANK and MUFG Bank advised the Japanese listed chemical company Daicel on the sale of its German subsidiary Lomapharm to Bionorica as part of an international bidding process. This is already the third sale of Lomapharm that DZ BANK has had the privilege of accompanying.

Founded in 1878, Lomapharm specializes in the production of medicinal products and food supplements as well as medical devices on behalf of customers. With around 165 employees based in Emmerthal, Germany, the company provides best-in-class services to its customers.
Bionorica, headquartered in Neumarkt, Germany, is a leading global manufacturer of scientifically researched herbal medicines with around 1,800 employees and annual sales of € 288 million (2021A). The company is considered the leader in the phytopharmaceutical market in Germany and Europe, based on turnover or units sold in pharmacies.


Advised in the sale of

Lomapharm (part of Daicel Group)




MidCap Alliance